Seres Therapeutics (MCRB) Cash from Financing Activities (2014 - 2026)

Seres Therapeutics has reported Cash from Financing Activities for 13 years, with the latest figure at $428000.0 in Q1 2026.

• Quarterly Cash from Financing Activities fell 63.73% year-over-year to $428000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.1 million (up 112.18% YoY) and the FY2025 annual result came in at $13.9 million, up 115.38% from the prior year.
• Cash from Financing Activities eased to $428000.0 in Q1 2026 per MCRB's latest filing, from $12.7 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $98.0 million in Q3 2022 and troughed at -$110.9 million in Q3 2024.
• A 5-year average of $8.4 million and a median of $4.6 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities jumped 44651.54% in 2023, then plunged 7783.37% in 2024.
• Over 5 years, Cash from Financing Activities stood at $4.6 million in 2022, then soared by 39.85% to $6.4 million in 2023, then tumbled by 72.98% to $1.7 million in 2024, then surged by 628.67% to $12.7 million in 2025, then slumped by 96.62% to $428000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $428000.0, $12.7 million, and $61000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.